Funding moves Platform Technology Forward
Dec 05 2019 Read 1118 Times
Completion of a $13.5M financing round, will see Munich-based GNA Biosolutions GmbH advance development and secure IVD-CE marking of its first Point of Care molecular diagnostic platform which uses Pulse Controlled Amplification (PCA), which amplifies nucleic acids captured directly from complex samples.
“We are excited to work with the GNA team and look forward to supporting this stage of the company. Rapid molecular diagnostics are key to patient care across an increasingly broad range of therapeutic areas and particularly infectious diseases. We believe PCA technology will resolve many limitations of existing molecular diagnostics, enabling fast therapeutic decisions that improve patient care,” said Tom Miller, partner at GreyBird Ventures, (USA) lead investor for the round. Mr. Miller, a global healthcare industry leader and an experienced and visionary CEO, will serve as Chairman of GNA’s Board effective immediately.
“We are very appreciative of the enthusiastic response from our new investors and the continued support of our existing consortium. This Series C funding will help us execute our regulatory strategy and bring PCA to the clinic,” said Federico Buersgens, co-founder and Managing Director of GNA Biosolutions. GNA plans to launch its POC platform first in the EU, followed by the US. “We believe having this unique combination of European and US investors on board gives GNA an edge – we have assembled a great consortium which will provide us not only with a tremendous depth of experience but also visibility and access to decision makers across our key launch markets” said Mr. Buersgens.
GNA’s breakthrough technology allows the development of cost effective and simple-to-perform molecular diagnostic tests. The company’s prototype platform has been utilised in more than 30 assays in-house and with partners, including assays for Hospital Acquired Infections and Tuberculosis, and biothreats such as Ebola and Plague.
GNA is the winner of AACC’s 2018 Disruptive Technology Award and a Showcase Company in the 2019 MedTech Innovator Competition.
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Mass Spectrometry & Spectroscopy - Translating Proteomic MALDi Tissue Typing to Clinical Pathology - Fusion Protein Complexes Analysed by CG-MALS - Non-equivalent, Multivalen...
View all digital editions
Jan 25 2020 San Diego, CA, USA
Jan 27 2020 Dubai, UAE
Jan 29 2020 Tokyo, Japan
Feb 03 2020 Dubai, UAE
Feb 12 2020 Tokyo, Japan